{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:16:57Z","timestamp":1790770617038,"version":"4.1.0"},"reference-count":9,"publisher":"BMJ","issue":"5","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Br J Ophthalmol"],"accepted":{"date-parts":[[2024,7,21]]},"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:p>Prior studies of teprotumumab for thyroid eye disease report proptosis reduction in millimetres, which does not fully capture teprotumumab\u2019s clinical effect since a given number of millimetres change can be of variable impact depending on patients\u2019 degree of pre-treatment proptosis. In this retrospective study analysing proptosis change as a percentage of pre-treatment proptosis among 119 patients, 208 (87.4%) eyes of 110 patients had proptosis reduction averaging 14.4% (range 2.2\u201340.5%) of their pre-treatment proptosis, or 3.3\u2009mm (range 0.5\u201310.0\u2009mm). Reporting proptosis reduction as a percentage of pre-treatment proptosis provides a better understanding of teprotumumab\u2019s clinical impact.<\/jats:p>","DOI":"10.1136\/bjo-2024-325527","type":"journal-article","created":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T13:20:26Z","timestamp":1724505626000},"page":"628-630","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Percent reduction in proptosis after teprotumumab treatment for thyroid eye disease"],"prefix":"10.1136","volume":"109","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1694-405X","authenticated-orcid":false,"given":"Tatiana R","family":"Rosenblatt","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Massachusetts Eye and Ear, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina A","family":"Chiou","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Massachusetts Eye and Ear, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael K","family":"Yoon","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Massachusetts Eye and Ear, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nahyoung Grace","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Massachusetts Eye and Ear, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1524-115X","authenticated-orcid":false,"given":"Natalie","family":"Wolkow","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Massachusetts Eye and Ear, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne K","family":"Freitag","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Massachusetts Eye and Ear, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,8,24]]},"reference":[{"key":"2025071523150773000_109.5.628.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0905750"},{"key":"2025071523150773000_109.5.628.2","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/0140-6736(91)90013-F","article-title":"Thyroid-associated eye disease: pathophysiology","volume":"338","author":"Weetman","year":"1991","journal-title":"The Lancet"},{"key":"2025071523150773000_109.5.628.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1614949"},{"key":"2025071523150773000_109.5.628.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910434"},{"key":"2025071523150773000_109.5.628.5","doi-asserted-by":"crossref","DOI":"10.1186\/s13044-020-00086-7","article-title":"Teprotumumab: a disease modifying treatment for graves\u2019 orbitopathy","volume":"13","author":"Ting","year":"2020","journal-title":"Thyroid Res"},{"key":"2025071523150773000_109.5.628.6","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2021.6284"},{"key":"2025071523150773000_109.5.628.7","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-018-0321-y"},{"key":"2025071523150773000_109.5.628.8","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-015-3156-2"},{"key":"2025071523150773000_109.5.628.9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1993.tb00516.x"}],"container-title":["British Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bjo-2024-325527","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T06:15:19Z","timestamp":1752646519000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjo.bmj.com\/lookup\/doi\/10.1136\/bjo-2024-325527"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,24]]},"references-count":9,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,4,22]]},"published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.1136\/bjo-2024-325527"],"URL":"https:\/\/doi.org\/10.1136\/bjo-2024-325527","relation":{},"ISSN":["0007-1161","1468-2079"],"issn-type":[{"value":"0007-1161","type":"print"},{"value":"1468-2079","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,24]]}}}